Navigation Links
Nitto Denko Avecia Inc. Strengthens its Commitment to the Small Molecule and Radiochemistry Industries by Hiring Hamilton J. Lenox as Director of Business Development

(PRWEB) December 19, 2013

Nitto Denko Avecia Inc., an industry leader in process development and commercial manufacturing, is proud to announce that it has hired Hamilton J. Lenox as its new Director of Business Development. Hamilton initially will focus on the small molecule and radiochemistry units of Avecia, and also will be handling marketing for the organization. Hamilton brings both a strong technical background and significant business development expertise to Avecia, including familiarity both with clients and the outsourcing markets in North America, Europe and Asia.

The hiring of Hamilton, who is well known in the small molecule industry, demonstrates Avecia’s continuing commitment to their small molecule and radiochemistry customers. Early in 2013 Avecia acquired the contract manufacturing business of Girindus America Inc., adding small molecule API manufacturing and radiochemistry capabilities while expanding Avecia’s best in class oligonucleotide offerings.

Hamilton says he is excited to join Nitto Denko Avecia, Inc., a company well-known for their excellent reputation and strong leadership. “I look forward to expanding our client base in my new role, and know our existing and future clients will continue to be impressed with Avecia’s commitment to quality in everything we do,” says Hamilton. He notes that the acquisition of Girindus America’s contract manufacturing business not only keeps Avecia positioned as the leader of the oligonucleotide manufacturing market, but also significantly expands their capabilities.

Additionally, small molecule services have complemented Avecia’s oligonucleotide business due to both units’ expertise in difficult conjugation chemistry, and Avecia now can produce any necessary small molecule linkers / conjugates in-house. The expertise of Avecia’s oligo team also has benefited the small molecule unit by providing additional expertise that clearly positions Avecia as a leader in developing and manufacturing small molecule nucleotide derivatives and analogs. There also is a strong synergy between the oligo and radiochemistry units, as this combination marks Avecia as one of the only radiochemistry facilities in the world with significant expertise in oligo synthesis.

About Nitto Denko Avecia, Inc.:
Nitto Denko Avecia, Inc., is a drug development and manufacturing services company with headquarters in Milford, MA, and is a part of Nitto Denko Corporation, Japan’s leading diversified materials manufacturer. Avecia is a recognized leader in the oligonucleotide therapeutic market, and with the acquisition of Girindus America’s contract manufacturing business in 2013 has added radiochemistry and small molecule API development and manufacturing to its portfolio of services. Avecia’s oligonucleotide facilities (in Milford, MA, and Cincinnati, OH) support DNA and RNA-based therapeutics throughout their lifecycle, and include such services as process and analytical development and pre-clinical production through large scale cGMP commercial manufacturing. To see what Avecia can do for your business, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. NITTO DENKO Avecia Inc. Introduces Dedicated Pre-Clinical Oligonucleotide Service, OliGrow
2. Intrexon Strengthens Leadership in Companys Rapidly Growing Health Sector
3. Gallus Strengthens Biologics CMO Business with Acquisition of Laureate
4. inVentiv Health Clinical Expands and Strengthens Executive Team with Three Strategic Appointments
5. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
6. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
7. Cytos Biotechnology Strengthens Management Team
8. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
9. Molecular Detection Inc. Further Strengthens Patent Portfolio Broadly Covering Detection of Antibiotic-Resistant Bacteria
10. AMRI Strengthens Business Development and Marketing Groups
11. Hospira Names Zena G. Kaufman Senior Vice President of Quality; Strengthens Quality and Compliance Capabilities With Addition of Top Industry Talent
Post Your Comments:
(Date:11/27/2015)... 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ... it has closed the sale of its global contrast ... NYSE Euronext) in a transaction valued at approximately $270 ... and a total of approximately 1,000 employees spread across ... St. Louis area. This entire workforce and ...
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
Breaking Biology News(10 mins):